Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing a novel class of biological drugs, which we refer to as Ecobiotic microbiome therapeutics, that are designed to restore health by repairing the function of a dysbiotic microbiome. The Company’s lead product candidate, SER-109, is intended to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon, and, if approved by the FDA, could be a first-in-field drug. Using its...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 9, 2018--
Therapeutics, Inc. (NASDAQ:MCRB) today announced it will present at
each of the following upcoming healthcare conferences:
The 38th Annual Cowen & Co. Health Care
Conference: a corporate overview will be presented on Wednesday,
March 14 at 10:40 a.m. ET in Boston, MA.
Oppenheimer's 28th Annual Healthcare
Conference: a corporate overview wil...
- Positive SER-287 Phase 1b clinical and microbiome results support
further development; Company plans to initiate next clinical trial in
- Preliminary Phase 1b study data obtained for SER-262, the first
ever rationally-designed fermented microbiome therapeutic candidate
evaluated in humans–
- Collaboration with MD Anderson and Parker Institute intends to
initiate clinical study in 2018 to evaluate microbiome therapeutic...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 2, 2018--
Therapeutics, Inc. (NASDAQ:MCRB) today announced that management
will host a conference call and live audio webcast on March 8, 2018 at
8:00 a.m. ET to discuss fourth quarter 2017 results and provide a
general business update.
To access the conference call, please dial 844-277-9450 (domestic) or
336-525-7139 (international) and reference the conference ID number
5092388. To joi...